{"id":"NCT00234533","sponsor":"Ipsen","briefTitle":"Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq","officialTitle":"Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2005-10-07","resultsPosted":"2018-08-09","lastUpdate":"2019-12-09"},"enrollment":251,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Turner Syndrome","Renal Insufficiency, Chronic","Pituitary Diseases","Dwarfism"],"interventions":[{"type":"DRUG","name":"Somatropin (rDNA origin)","otherNames":[]}],"arms":[{"label":"NutropinAq 10 mg/2 mL (30 IU)","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.","primaryOutcome":{"measure":"Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples","timeFrame":"At Weeks 21, 22 and 23","effectByArm":[{"arm":"NutropinAq 10 mg/2 ml (30 IU)","deltaMin":223.54,"sd":161.86}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":45,"countries":["Belgium","Czechia","Denmark","Finland","France","Germany","Greece","Italy","Romania","Russia","Slovakia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":248},"commonTop":["Headache","Insulin-like Growth Factor increased","Pyrexia","Upper respiratory tract infection","Rhinitis"]}}